Nederlandse reactie op gerichte consultatie over herziening EMA-vergoedingensysteem

The European Commission (EC) has issued a marketing authorisation for Sanofi Genzyme’s therapy Nexviadyme (avalglucosidase alfa) for the long-term treatment of both late-onset and infantile-onset Pompe disease. Pompe...

AbbVie has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for atogepant as a migraine treatment for adults who have at least four migraine days per month. Atogepant is an...

Additional findings were announced from a phase 2/3 study evaluating the efficacy and safety of Paxlovid (nirmatrelvir tablets co-packaged with ritonavir tablets) in patients with COVID-19 who are at standard risk of...